Cynthia Smith - Jun 10, 2025 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
Director
Signature
/s / Carolyn Rucci, attorney-in-fact for Cynthia Smith
Stock symbol
AKBA
Transactions as of
Jun 10, 2025
Transactions value $
$0
Form type
4
Date filed
6/11/2025, 05:15 PM
Previous filing
Apr 21, 2025
Next filing
Jun 13, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Smith Cynthia Director C/O AKEBIA THERAPEUTICS, INC, 245 FIRST STREET, CAMBRIDGE /s / Carolyn Rucci, attorney-in-fact for Cynthia Smith 2025-06-11 0001609480

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +35.7K +28.51% $0.00 161K Jun 10, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Award $0 +53.6K $0.00 53.6K Jun 10, 2025 Common Stock 53.6K $3.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
F2 The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.